Lucrative Novo Nordisk business segment suffers headwind
Business squeezed by the succes of the diabetes and obesity business,” says analyst.
by marketwire
Things are going south at Novo Nordisk in the business area with the umbrella term rare diseases. CEO Lars Fruergaard is having problems with the production of the drug Norditropin, which is hampering sales of the otherwise lucrative growth hormone, writes Danish daily Jyllands-Posten.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
